Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab

Parisa Yousefpour1, Fatemeh Atyabi2, Ebrahim Vasheghani-Farahani3, Ali-Akbar Mousavi Movahedi1, Rassoul Dinarvand21Department of Biotechnology, Faculty of Science, University of Tehran, 2Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, 3Biotechnology Group,...

Full description

Bibliographic Details
Main Authors:	Yousefpour P, Atyabi F, Vasheghani-Farahani E, Mousavi Movahedi AA, Dinarv, R
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-09-01
Series:	International Journal of Nanomedicine
Online Access:	http://www.dovepress.com/targeted-delivery-of-doxorubicin-utilizing-chitosan-nanoparticles-surf-a8281

Similar Items

Polyanionic carbohydrate doxorubicin&ndash;dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations
by: Yousefpour P, et al.
Published: (2011-07-01)

Chitosan&ndash;Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study
by: Ostad SN, et al.
Published: (2012-04-01)

Magnetic chitosan nanoparticles for doxorubicin delivery
by: Chung Lin Yang, et al.
Published: (2010)

Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells
by: Talaei F, et al.
Published: (2011-09-01)

Preparation and in vitro drug delivery response of doxorubicin loaded PAA coated magnetite nanoparticles
by: Omidirad Reyhan, et al.
Published: (2013-01-01)

Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
by: Naruphontjirakul P, et al.
Published: (2019-06-01)

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
by: Rouhani H, et al.
Published: (2011-04-01)

Determination of the Optimum Conditions for Production of Chitosan Nanoparticles
by: A. Dustgani, et al.
Published: (2007-12-01)

Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
by: Noori Koopaei M, et al.
Published: (2011-09-01)

Retinoic Acid Decorated Albumin-Chitosan Nanoparticles for Targeted Delivery of Doxorubicin Hydrochloride in Hepatocellular Carcinoma
by: Jaleh Varshosaz, et al.
Published: (2013-01-01)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
by: Ibrahim Sadek, et al.
Published: (2017-09-01)

Targeted delivery of doxorubicin to HER2 positive tumor models
by: Gomari H, et al.
Published: (2019-07-01)

Enhanced Intestinal Permeation of Doxorubicin Using Chitosan Nanoparticles
by: Marziyeh Zare, et al.
Published: (2018-08-01)

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
by: Andrea Rocca, et al.
Published: (2021-02-01)

Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
by: Yiwen You, et al.
Published: (2018-01-01)

Preparation and Characterization of Drug-Delivery System of Chitosan Nanoparticles Containing Doxorubicin for Use in the Treatment of Breast Cancer
by: Sedigheh Vaezifar, et al.
Published: (2019-12-01)

Preparation and evaluation of SiO2-deposited stearic acid-g-chitosan nanoparticles for doxorubicin delivery
by: Yuan H, et al.
Published: (2012-09-01)

Biocompatible Chitosan Nanobubbles for Ultrasound-Mediated Targeted Delivery of Doxorubicin
by: Xiaoying Zhou, et al.
Published: (2019-01-01)

Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
by: Stefania Gorini, et al.
Published: (2018-01-01)

Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
by: Martin Nicol, et al.
Published: (2021-04-01)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
by: Gomari H, et al.
Published: (2019-09-01)

The Effect of Process Variables on the Properties of Ketoprofen Loaded Solid Lipid Nanoparticles of Beeswax and Carnauba Wax
by: Soheila Kheradmandnia, et al.
Published: (2010-12-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

Hypoxia-Responsive Mesoporous Nanoparticles for Doxorubicin Delivery
by: Shakera Khatoon, et al.
Published: (2018-04-01)

Enhanced Oral Delivery of Docetaxel Using Thiolated Chitosan Nanoparticles: Preparation, In Vitro and In Vivo Studies
by: Shahrooz Saremi, et al.
Published: (2013-01-01)

Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.
by: Alejandro Vazquez-Martin, et al.
Published: (2009-01-01)

Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
by: Stefania Gorini, et al.
Published: (2019-01-01)

The cardioprotective role of NACA in the prevention of Doxorubicin and Trastuzumab mediated cardiac dysfunction
by: Goyal, Vineet
Published: (2015)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
by: Qiaoping Xu, et al.
Published: (2021-02-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer
by: Rama Prajapati, et al.
Published: (2021-06-01)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019-11-01)

Chitosan-Alginate Nanoparticle System Efficiently Delivers Doxorubicin to MCF-7 Cells
by: Nuwanthi P. Katuwavila, et al.
Published: (2016-01-01)

Magnetic chitosan nanoparticles for camptothecin delivery
by: Hsin-Ho Li, et al.
Published: (2013)

Intracellular delivery of doxorubicin encapsulated in novel pH-responsive chitosan/heparin nanocapsules
by: Thomas MB, et al.
Published: (2013-01-01)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
by: Daisuke Kotani, et al.
Published: (2021-01-01)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
by: Tiziana Triulzi, et al.
Published: (2019-01-01)